HomeNewsTicogrelor monotherapy post PCI associated with similar rates of revascularization as duel antiplatelet therapy
20Май
Ticogrelor monotherapy post PCI associated with similar rates of revascularization as duel antiplatelet therapy
by
New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor plus aspirin was associated with similar rates of recurrent coronary revascularization, major adverse cardiac and cerebrovascular events (MACCE) and a lower risk of net adverse clinical events (NACE) compared with duel antiplatelet therapy (DAPT). The results from the randomized control trial of more than 7,000 patients were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions.